Biomarqueurs pronostiques et pr¡§|dictifs des cancers bronchiques non ¡§¡è petites cellules. Des autorisations de mise sur le march¡§| ??conditionn¡§|es?? ¡§¡è la cartographie mol¡§|culaire de routine des cancers bronchiques?: les limites m¡§|thodolo

详细信息    查看全文

• 作者：Emmanuel Bergot¹ ; ² ; ³ ; Gué ; naë ; lle Levallet² ; ³ ; ⁴ ; Christian Creveuil⁵ ; Emmanuè ; le Lechapt⁴ ; Gerard Zalcman¹ ; ² ; ³ ; ^{zalcman-g@chu-caen.fr}
• 刊名：La Presse M¡§|dicale
• 出版年：2011
• 出版时间：April 2011
• 年：2011
• 卷：40
• 期：4_part_P1
• 页码：379-388
• 全文大小：257 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Key points

Targeted therapies booming and new efficacious cytotoxics emergence in non-small cell lung cancers (NSCLC) deeply changed prognosis in some subsets of patients experiencing long survival.

A priori identification (at time of diagnosis) of patients the most beneficiating from those often costly therapies is the new issue in thoracic oncology.

For EGFR tyosine kinase inhibitors (TKI), molecular targeting relies on EGFR mutations diagnosis, that led to the first conditioned molecular-based registration for a drug in thoracic oncology, that was made easier in France by French NCI huge effort to sponsor the 28 regional molecular biology platforms.

For the majority of classical cytotoxics used in adjuvant treatment after lung cancer surgical resection, biomarkers relying on immunohistochemistry still need further prospective validation steps before routine use.

Prospective validation studies aimed to evaluate the ability of those biomarkers to predict not only response to therapy, but also survival with a specific treatment (predictive value), need large phase 3 trials with centralized biomarker analyses and rigorous statistical methods.

French Intergroup (IFCT) has initiated such studies that will help to validate new biomarkers that we may use routinely in lung cancer in near future.